NZ598861A - Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury - Google Patents
Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injuryInfo
- Publication number
- NZ598861A NZ598861A NZ598861A NZ59886110A NZ598861A NZ 598861 A NZ598861 A NZ 598861A NZ 598861 A NZ598861 A NZ 598861A NZ 59886110 A NZ59886110 A NZ 59886110A NZ 598861 A NZ598861 A NZ 598861A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disease
- medical condition
- hepes
- piperazine
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24346409P | 2009-09-17 | 2009-09-17 | |
| PCT/US2010/049405 WO2011035212A2 (en) | 2009-09-17 | 2010-09-17 | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598861A true NZ598861A (en) | 2013-01-25 |
Family
ID=43757159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598861A NZ598861A (en) | 2009-09-17 | 2010-09-17 | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8883855B2 (enExample) |
| EP (3) | EP2477626A4 (enExample) |
| JP (4) | JP2013505264A (enExample) |
| KR (1) | KR101737775B1 (enExample) |
| CN (4) | CN107260740A (enExample) |
| AR (1) | AR078290A1 (enExample) |
| AU (1) | AU2010295445B2 (enExample) |
| BR (1) | BR112012006155A2 (enExample) |
| CA (3) | CA3122553A1 (enExample) |
| HK (1) | HK1199621A1 (enExample) |
| IL (2) | IL264055B2 (enExample) |
| IN (1) | IN2012DN02499A (enExample) |
| MX (2) | MX360190B (enExample) |
| MY (2) | MY174012A (enExample) |
| NZ (1) | NZ598861A (enExample) |
| SG (3) | SG179191A1 (enExample) |
| TW (2) | TWI494106B (enExample) |
| WO (1) | WO2011035212A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867820B2 (en) | 2009-09-17 | 2018-01-16 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2956919C (en) | 2014-07-21 | 2022-07-19 | Glia, Llc | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids |
| CA2984379C (en) * | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| WO1997002270A1 (de) | 1995-07-06 | 1997-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Thiolsilane, verfahren zu deren herstellung und deren verwendung |
| US5716959A (en) * | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
| NZ550199A (en) * | 1998-02-11 | 2008-07-31 | Bellus Health Int Ltd | Treatment of inflammation, abeta-induced cell toxicity, neuronal cell death or neuronal cell loss in subjects suffering from alzheimer's disease |
| US9044478B2 (en) | 2004-11-10 | 2015-06-02 | Institut National De La Sante Et De La Recherche Medicale | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| JP2010532331A (ja) * | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| EP2011491A1 (en) | 2007-07-05 | 2009-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticonvulsive pharmaceutical compositions |
| EP2163246A1 (en) * | 2008-09-12 | 2010-03-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin |
| US8709299B2 (en) | 2009-09-04 | 2014-04-29 | Basf Se | Dye sensitised solar cell |
| AU2014206220B2 (en) | 2009-09-17 | 2016-09-29 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
| MY174012A (en) | 2009-09-17 | 2020-03-03 | Bespoke Bioscience Llc | Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
-
2010
- 2010-09-17 MY MYPI2015002505A patent/MY174012A/en unknown
- 2010-09-17 CN CN201710494640.6A patent/CN107260740A/zh active Pending
- 2010-09-17 CA CA3122553A patent/CA3122553A1/en active Pending
- 2010-09-17 JP JP2012529955A patent/JP2013505264A/ja active Pending
- 2010-09-17 MX MX2015008916A patent/MX360190B/es unknown
- 2010-09-17 EP EP10817952.4A patent/EP2477626A4/en not_active Withdrawn
- 2010-09-17 SG SG2012018842A patent/SG179191A1/en unknown
- 2010-09-17 CA CA2774375A patent/CA2774375C/en active Active
- 2010-09-17 AU AU2010295445A patent/AU2010295445B2/en active Active
- 2010-09-17 KR KR1020127009683A patent/KR101737775B1/ko active Active
- 2010-09-17 SG SG10201500510YA patent/SG10201500510YA/en unknown
- 2010-09-17 US US12/885,404 patent/US8883855B2/en active Active
- 2010-09-17 TW TW099131755A patent/TWI494106B/zh active
- 2010-09-17 WO PCT/US2010/049405 patent/WO2011035212A2/en not_active Ceased
- 2010-09-17 BR BR112012006155A patent/BR112012006155A2/pt not_active Application Discontinuation
- 2010-09-17 EP EP19161338.9A patent/EP3520794A3/en active Pending
- 2010-09-17 CN CN201811365002.5A patent/CN109224077A/zh active Pending
- 2010-09-17 SG SG10202100421XA patent/SG10202100421XA/en unknown
- 2010-09-17 IL IL264055A patent/IL264055B2/en unknown
- 2010-09-17 EP EP14191925.8A patent/EP2835133B1/en active Active
- 2010-09-17 MY MYPI2012001195A patent/MY159626A/en unknown
- 2010-09-17 AR ARP100103407A patent/AR078290A1/es unknown
- 2010-09-17 MX MX2012003212A patent/MX2012003212A/es active IP Right Grant
- 2010-09-17 CN CN201410166019.3A patent/CN103977405A/zh active Pending
- 2010-09-17 NZ NZ598861A patent/NZ598861A/xx unknown
- 2010-09-17 CN CN2010800521032A patent/CN102612366A/zh active Pending
- 2010-09-17 TW TW103124615A patent/TWI562777B/zh active
- 2010-09-17 CA CA2977918A patent/CA2977918C/en active Active
-
2012
- 2012-03-15 IL IL218677A patent/IL218677B/en active IP Right Grant
- 2012-03-22 IN IN2499DEN2012 patent/IN2012DN02499A/en unknown
-
2014
- 2014-09-09 US US14/481,582 patent/US9867820B2/en active Active
- 2014-11-14 JP JP2014231168A patent/JP5974062B2/ja active Active
-
2015
- 2015-01-06 HK HK15100074.2A patent/HK1199621A1/xx unknown
- 2015-02-10 JP JP2015024177A patent/JP2015129150A/ja active Pending
-
2016
- 2016-07-15 JP JP2016140167A patent/JP6347807B2/ja active Active
-
2017
- 2017-10-04 US US15/725,007 patent/US10213425B2/en active Active
-
2019
- 2019-01-14 US US16/247,233 patent/US20190142825A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867820B2 (en) | 2009-09-17 | 2018-01-16 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
| US10213425B2 (en) | 2009-09-17 | 2019-02-26 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| WO2007136518A3 (en) | Treatment of autoimmune disorders | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| CO6361928A2 (es) | Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| WO2011119227A3 (en) | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients | |
| RU2008116931A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| WO2008103472A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| NZ593467A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| MX2008013635A (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| UA98462C2 (ru) | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig | |
| BRPI0513168A (pt) | memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia | |
| SE0400184D0 (sv) | New therapeutical use | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| NZ598861A (en) | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| SV2001000465A (es) | Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE POSTPONEMENT PERIOD HAS BEEN CORRECTED TO 0 Effective date: 20130103 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2017 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS Effective date: 20140904 |
|
| ASS | Change of ownership |
Owner name: BESPOKE BIOSCIENCE, LLC, US Effective date: 20141127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20170720 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2019 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20180720 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20190718 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2021 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20200831 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2022 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20210813 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2023 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20220809 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2024 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20230809 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2025 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20240910 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2026 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20250905 |